Local delivery of recombinant adenovirus expressing hepatitis B virus X protein and interleukin-12 results in antitumor effects via inhibition of hepatoma cell growth and intervention of tumor microenvironment

RP BeasleyRocks along the road to the control of HBV and HCCAnn Epidemiol19231234200910.1016/j.annepidem.2009.01.01719344859

K OkudaHepatocellular carcinomaJ Hepatol32225237200010.1016/S0168-8278(00)80428-6

H TangN OishiS KanekoS MurakamiMolecular functions and biological roles of hepatitis B virus x proteinCancer Sci97977983200610.1111/j.1349-7006.2006.00299.x16984372

P ChengY LiL YangHepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinaseOncol Rep22110111072009

T TianKJ NanSH WangPTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cellsCarcinogenesis3112111219201010.1093/carcin/bgq08520430845

M FernandezD SemelaJ BruixI ColleM PinzaniJ BoschAngiogenesis in liver diseaseJ Hepatol50604620200910.1016/j.jhep.2008.12.011

L LiuY CaoC ChenSorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Cancer Res661185111858200610.1158/0008-5472.CAN-06-137717178882

X ChenX LinJ ZhaoA tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCsMol Ther16749756200810.1038/mt.2008.318362930

C GuiducciAP VicariS SangalettiG TrinchieriMP ColomboRedirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejectionCancer Res6534373446200515833879

E ChunJ LeeHS CheongKY LeeTumor eradication by hepatitis B virus X antigen-specific CD8⁺ T cells in xenografted nude miceJ Immunol17011831190200310.4049/jimmunol.170.3.118312538674

Y LiP ChengY WenT lymphocyte responses against hepatitis B virus-related hepatocellular carcinoma induced by adenovirus vaccine encoding HBxInt J Mol Med268698762010

FX DingF WangYM LuMultiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinomaHepatology4914921502200910.1002/hep.2281619206147

YJ WangY HouH HuangGR LiuAP WhiteSL LiuTwo oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunityCancer Lett2636776200810.1016/j.canlet.2007.12.02218226855

A HombachC HeuserH AbkenSimultaneous targeting of IL2 and IL12 to Hodgkin’s lymphoma cells enhances activation of resting NK cells and tumor cell lysisInt J Cancer1152412472005

C HalinS RondiniF NilssonEnhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculatureNat Biotechnol20264269200210.1038/nbt0302-26411875427

LS PengML PenichetSL MorrisonA single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activityJ Immunol1632502581999

JA HendrzakMJ BrundaAntitumor and antimetastatic activity of interleukin-12Curr Top Microbiol Immunol21365831996

G TrinchieriImmunobiology of interleukin-12Immunol Res17269278199810.1007/BF02786451

Y NasuCH BangmaGW HullCombination gene therapy with adenoviral vector-mediated HSV-tk⁺ GCV and IL-12 in an orthotopic mouse model for prostate cancerProstate Cancer Prostatic Dis44451200110.1038/sj.pcan.450049412497062

CM CouglinKE SalhangM WysockaInterleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesisJ Clin Invest10114411452199810.1172/JCI15559502787

BM PützerM HittWJ MullerInterleukin 12 and B7-1 co-stimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regressionProc Natl Acad Sci USA94108891089519979380730

JD BuiR UppaluriCS HsiehRD SchreiberComparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar originsCancer Res6673017309200610.1158/0008-5472.CAN-06-055616849580

M KortylewskiP SwiderskiA HerrmannIn vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responsesNat Biotechnol27925932200910.1038/nbt.156419749770

M KujawskiM KortylewskiH LeeA HerrmannH KayH YuStat3 mediates myeloid cell-dependent tumor angiogenesis in miceJ Clin Invest11833673377200810.1172/JCI3521318776941

LM CoussensZ WerbInflammation and cancerNature420860867200210.1038/nature0132212490959

A MantovaniS SozzaniM LocatiP AllavenaA SicaMacrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytesTrends Immunol23549555200210.1016/S1471-4906(02)02302-512401408

PC RodriguezMS ErnstoffC HernandezArginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytesCancer Res6915531560200910.1158/0008-5472.CAN-08-192119201693

LA NorianPC RodriguezLA O’MaraTumor-infiltrating regulatory dendritic cells inhibit CD8⁺ T cell function via L-arginine metabolismCancer Res6930863094200910.1158/0008-5472.CAN-08-282619293186

SJ PiersmaES JordanovaMI van PoelgeestHigh number of intraepithelial CD8⁺ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancerCancer Res67354361200717210718

AG MenonGJ FleurenEA AlphenaarA basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancerCancer Immunol Immunother521211262003

E SatoSH OlsonJ AhnIntraepithelial CD8⁺ tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerProc Natl Acad Sci USA10218538185432005

L ZhangJR Conejo-GarciaD KatsarosIntratumoral T cells, recurrence, and survival in epithelial ovarian cancerN Engl J Med348203213200310.1056/NEJMoa02017712529460

O SimmaE ZebedinN NeugebauerIdentification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillanceCancer Res69203211200910.1158/0008-5472.CAN-08-170519118004

MN TorreroX XiaW HenkS YuS LiStat1 deficiency in the host enhances interleukin-12-mediated tumor regressionCancer Res6644614467200610.1158/0008-5472.CAN-05-355416618773

H KanzlerFJ BarratEM HesselRL CoffmanTherapeutic targeting of innate immunity with Toll-like receptor agonists and antagonistsNat Med13552559200710.1038/nm158917479101

W BarchetV WimmenauerM SchleeG HartmannAccessing the therapeutic potential of immunostimulatory nucleic acidsCurr Opin Immunol20389395200810.1016/j.coi.2008.07.00718652893

CS TannenbaumN WickerD ArmstrongCytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12J Immunol15669369919968543822

S AdrisE ChuluyanA BravoMice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cellsCancer Res6066966703200011118055

CL NastalaHD EdingtonTG McKinneyRecombinant IL-12 administration induces tumor regression in association with IFN-gamma productionJ Immunol1531697170619947913943

AD LusterP LederIP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivoJ Exp Med17810571065199310.1084/jem.178.3.10578350046